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The nucleocapsid (N) protein of all morbilliviruses has a highly conserved central region that is
thought to interact with and encapsidate the viral RNA. The C-terminal third of the N protein is
highly variable among morbilliviruses and is thought to be located on the outer surface and to
be available to interact with other viral proteins such as the phosphoprotein, the polymerase
protein and the matrix protein. Using reverse genetics, a chimeric rinderpest virus (RPV)/
peste-des-petits-ruminants virus (PPRV) was rescued in which the RPV N gene open reading
frame had been replaced with that of PPRV (RPV–PPRN). The chimeric virus maintained efficient
replication in cell culture. Cattle vaccinated with this chimeric vaccine showed no adverse
reaction and were protected from subsequent challenge with wild-type RPV, indicating it to be
a safe and efficacious vaccine. The carboxyl-terminal variable region of the rinderpest N protein
was cloned and expressed in Escherichia coli. The expressed protein was used to develop an
indirect ELISA that could clearly differentiate between RPV- and PPRV-infected animals. The
possibility of using this virus as a marker vaccine in association with a new diagnostic ELISA in the
rinderpest eradication programme is discussed.
INTRODUCTION
Rinderpest, or cattle plague, is an economically important
disease of domestic and wild ruminants. The disease is
caused by rinderpest virus (RPV), which is classified in the
genus Morbillivirus in the family Paramyxoviridae. The
morbillivirus genome consists of a single strand of negative-
sense RNA, which is organized into six contiguous, non-
overlapping transcription units encoding six structural
proteins, the nucleocapsid (N), polymerase (P), matrix
(M), fusion (F), haemagglutinin (H) and large (L) proteins,
in the order 39-N-P-M-F-H-L-59 (Bailey et al., 2005;
Crowley et al., 1988; Rima et al., 1986). In addition, there
are two non-structural proteins (C and V), which are
translated from the P gene open reading frame (ORF) by
co-transcriptional RNA editing (V) or from an overlapping
ORF (C) (Bellini et al., 1985; Cattaneo et al., 1989;
Mahapatra et al., 2003). The RNA genome is encapsidated
and protected by N protein and, like many viruses in the
family Paramyxoviridae, it complies with the ‘rule of six’,
i.e. the genomes must be an exact multiple of six, as each N
protein molecule is thought to interact with six nucleotides
(Calain & Roux, 1993). Computer alignment of morbilli-
virus N protein sequences has defined regions with varying
degrees of homology: the N-terminal part of the protein is
very well conserved, whilst the C-terminal region is found
to vary greatly among related viruses (Diallo et al., 1994).
The N protein is the most abundant of the structural
proteins by virtue of its position close to the promoter
(Cattaneo et al., 1987a, b) and it performs several functions
during virus replication. These include encapsidation of the
genomic RNA into an RNase-resistant ribonucleocapsid
(the template for RNA synthesis) and association with the
P/L polymerase complex (required for transcription and
replication); it also appears to interact with the M protein
during virus assembly (Buchholz et al., 1994; Coronel et al.,
2001; Curran, 1996; Curran et al., 1998; Ryan & Portner,
1990). We were interested in finding out whether this
protein, with such diverse interactions with other viral
proteins, could be substituted between closely related
morbilliviruses of ruminant species, namely RPV and
peste-des-petits-ruminants virus (PPRV). In this study, we
report the generation and characterization of a chimeric
RPV where the N protein gene of the RPV vaccine strain
was replaced with the equivalent gene from the PPRV
vaccine. The recombinant virus exhibited growth char-
acteristics in cell culture similar to those of the parental
viruses, and animals vaccinated with this chimeric virus
were protected from challenge with virulent virus.
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antigenic in nature. However, in the case of morbilliviruses,
N protein-specific immunity alone does not confer
protection (Nakamura et al., 1998; Ohishi et al., 1999).
The N protein has been used as an antigen for diagnostic
purposes for rabies virus (Katayama et al., 1999), measles
virus (MV) (Warnes et al., 1994), vesicular stomatitis virus
(Ahmad et al., 1993), Newcastle disease virus (NDV)
(Errington et al., 1995) and PPRV (Dechamma et al., 2006;
Libeau et al., 1995). Therefore, it appears to be a suitable
target for developing a marker vaccine for RPV, as it
involves swapping only one of the viral internal protein
genes between two virus vaccine strains. The C-terminal
variable region of the N protein of morbilliviruses has been
reported to protrude from the surface of the viral nucleo-
capsid (Heggeness et al., 1981) and is, therefore, a good
candidate for developing a test for RPV/PPRV differential
diagnosis. The C-terminal variable region of the RPV N
protein was expressed in Escherichia coli and used sub-
sequently to develop an indirect ELISA that could be used
for serological identification of animals vaccinated with the
chimeric vaccine. It is proposed that the chimeric virus,
when used in conjunction with the newly developed com-
panion serological test, would be suitable for use in the
final phase of the rinderpest eradication campaign.
METHODS
Cell culture and viruses. Vero cells (an African green monkey
kidney cell line) were grown in Dulbecco’s minimal essential medium
containing 25 mM HEPES (pH 7.2) and 5% fetal calf serum with
penicillin (100 IU ml
21) and streptomycin (100 mgm l
21).
Recombinant RPV (RPV2C) (Mahapatra et al., 2006) and the vaccine
strain of PPRV (Nigeria 75/1; Diallo et al., 1989) were grown in Vero
cells. When the cytopathic effect (CPE) was almost complete (usually
4–5 days for RPV and 8–9 days for PPRV), virus was harvested by a
single freeze–thaw cycle of infected cells and, after removal of cell
debris by centrifugation at 1280 g for 10 min, aliquots were stored at
270uC. Both RPV and PPRV were titrated on Vero cells by
determination of TCID50. The rescued recombinant virus was grown
and titrated on Vero cells as described above. Recombinant fowlpox
virus was grown in chicken embryo fibroblasts as previously described
(Mahapatra et al., 2006).
Plasmids and molecular biology techniques
All DNA manipulations and cloning were carried out using standard
protocols. The plasmids pKSN, pKS-P, pGEM-L and pRPV2C have
been described elsewhere (Baron & Barrett, 2000). Sequencing of
DNA was performed using the T7 sequencing kit (Pharmacia Biotech)
following the manufacturer’s instructions. RNA extraction from
cultures, purified peripheral blood lymphocytes (PBLs) and eye swabs
was carried out using Trizol (Invitrogen) as described by Mahapatra
et al. (2006). RT-PCR using Taq polymerase for analytical purposes
and Pfu polymerase for preparative purposes was performed using
standard protocols.
(i) Cloning of the N gene of PPRV and construction of full-length
genome plasmid. In order to manipulate the N gene, the restriction
sites ClaI (at the beginning of the N gene) and PacI (immediately after
the ORF of the N gene) of plasmid pRPV2C were used. Thus, the
same two restriction sites were incorporated into the PPRV N gene
copy. PPRV N gene sequence data (Diallo et al., 1994) was used to
design upstream primer PPRNF (59-GCGCATCGATATGGCTAC-
TCTCCTTA-39, nt 22–47 incorporating a ClaI site (underlined)
immediately before the N gene ORF and PPRNR (59-CGCG-
TTAATTAATGATTTGGACGGAGGGTGCGT-39, nt 1646–1614), in-
corporating a PacI restriction site (underlined) at the end of PPRV N
gene (25 nt downstream of the stop codon). The N gene ORF
was amplified using RNA from Vero cells infected with the PPRV
vaccine strain and the 1600 bp amplified product was cloned into the
vector pT7Blue. A clone containing the N gene ORF of PPRV
(pT7BluePPRN) was identified and completely sequenced on both
strands. The sequence was compared with the published sequence to
ensure that there were no PCR-induced mutations. The ClaI/PacI
digestion product of plasmid pT7BluePPRN was used to replace the
N gene ORF of pRPV2C to make the full-length genome plasmid
pRPV-PPRN. Restriction enzyme analysis was carried out to confirm
that the plasmids contained full-length copies of the viral genome
and the plasmid was sequenced to check that the N gene was from
PPRV.
(ii) Cloning of the C-terminal variable region of the N gene of RPV.
The C-terminal variable region of the rinderpest virus N gene
(RPVNv) was amplified using the upstream primer RPNF (59-
GCGTAGGATCCGAAATGGTAAGAAGGTCAGC-39, nt 1197–1227,
BamHI site underlined) and the downstream primer RPNR (59-
CTCGTGAAGCTTGTCGTTGTATGC-39, nt 1658–1681, HindIII site
underlined) using RNA from Vero cells infected with the RPV vaccine
strain (RBOK). The 462 bp amplified product was cloned into
pT7Blue and named pRPVNv. A clone was completely sequenced on
both the strands and the sequence was compared with the published
sequence to ensure that there were no PCR-induced mutations. The
BamHI/HindIII digestion product of the plasmid pRPVNv was ligated
into a similar site in the bacterial expression vector pQE30 (Qiagen)
to produce the plasmid pQE30-RPVNv. This vector adds an N-
terminal His tag to the coding sequence of the protein.
Expression and purification of His-tagged protein. To express
the protein, plasmid pQE30-RPVNv was transformed into E. coli
strain M15 (Novagen) and grown in NZYCM medium containing
ampicillin (50 mgm l
21) and kanamycin (25 mgm l
21). Expression
was carried out essentially as described in the manufacturer’s proto-
col. The protein was tested for its solubility and purified using
Ni-NTA resin (Qiagen). The protein samples were analysed by 12%
SDS-PAGE. The concentration of the protein was determined using a
protein assay kit (Bio-Rad).
Transfection and recovery of infectious recombinant virus.
Rescue of the chimeric virus genome was carried out using previously
described techniques (Parida et al., 2006). The rescued virus in the
transfected cell lysate was amplified by infecting Vero cells and
harvesting the virus when extensive CPE was observed. The identity of
the recombinant virus was confirmed by RT-PCR followed by
sequencing to ensure that the N gene was from PPRV. The plaque
morphology of the parental and recombinant viruses was assessed as
described by Das et al. (2000).
Growth of recombinant virus in tissue culture. Multi-step growth
curves were carried out by infecting Vero cells in six-well plates at
approximately 70% confluence with equal m.o.i. of recombinant and
the original parental viruses. Virus was allowed to adsorb to the cell
monolayers for 1–2 h and unbound virus was removed by washing
the cells three times with 2 ml growth medium. Finally, 2 ml growth
medium was added to each well and the cells were incubated for
different time periods. Each virus growth curve was carried out in
duplicate and at each time point (0, 12, 24, 36 and 48 h post-
infection), the infected cells were frozen at –70uC. The virus was
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virus was determined by measuring TCID50.
Animal studies. Healthy outbred Holstein Freisian bullock calves of
approximately 6–12 months of age were used for the vaccination trial,
which was carried out in accordance with national legislation
governing the use of animals for research and with the approval of
the local ethical review committee. Animals were housed in the
isolation facility of the Institute for Animal Health and observed for
4 weeks in the isolation unit before the start of the experiment to
ensure that they were in good health. Stocks of vaccine virus were
grown in Vero cells, and the challenge virus has been described
elsewhere (Walsh et al., 2000b). In this experiment, three cows were
vaccinated with RPV–PPRN (animal nos UQ11, UQ12 and UQ13)
and two with RPV vaccine (animal nos UQ9 and UQ10). Vaccine
virus (10
4 TCID50) was injected into the animals subcutaneously in
the shoulder region. All of the animals were challenged with 10
4
TCID50 virulent RPV (Saudi 1/81) 6 weeks after vaccination. The
animals were observed daily for the appearance of clinical signs of
rinderpest disease. Rectal temperatures and total leukocyte counts
were monitored for 2 weeks following vaccination and challenge.
Clinical samples were collected and analysed as described previously
(Das et al., 2000). In order to detect the viral RNA in clinical samples
(PBLs), a simple diagnostic PCR was carried out using primer set F3
and F4 (Forsyth & Barrett, 1995), specific for the RPV F gene. A
nested PCR using the primer set F3a (59-GCTCTGAACGCTATTA-
CTAAG-39, nt 845–865) and F4a (59-CTGCTTGTCGTATTTCCTC-
AA-39, nt 1079–1059) was also carried out to enhance the sensitivity
of detection of the viral RNA; this nested PCR was carried out only
on negative samples obtained from the PCR with the diagnostic
primer set (F3/F4). Tests for RPV-neutralizing antibodies were carried
out in microtitre plates following the method described in OIE
(2000).
ELISA for detection of H protein-specific antibodies. The virus-
specific antibody response was determined using the procedure
described by Anderson et al. (1996). This assay determines the
amount of antibody in a serum sample that recognizes a specific viral
antigen (RPV or PPRV H protein) by the ability of the sample to
inhibit binding of an antigen-specific monoclonal antibody (mAb) to
viral antigen. The results were expressed as the percentage inhibition
of binding of the control mAb. The cut-off value between negative
and positive serum was taken as 50% inhibition.
Competitive ELISA (cELISA) for detection of N protein-specific
antibodies. cELISA was carried out to measure the antibodies
against PPRV N protein using the method described by Libeau et al.
(1995). The cELISA carried out to measure the antibodies against
RPV N protein was essentially as described by Libeau et al. (1992),
except that the antigen used in the ELISA was prepared following the
protocol described by Anderson & McKay (1994).
Development of an indirect ELISA to detect RPV N-specific
antibodies using recombinant RPVNv protein. An indirect ELISA
was developed using E. coli-expressed RPVNv protein as the antigen.
Plates were coated with RPVNv protein (1 mg ml
21) at a 1 : 2000
dilution in carbonate/bicarbonate buffer (pH 9.6) for 1 h at 37uC.
After washing with normal PBS, the serum sample was added at a
1 : 8 dilution in blocking buffer containing 0.1% Tween 20 and 5%
Marvel in PBS and incubated for a further hour. After a thorough
wash, horseradish peroxidase-conjugated anti-bovine IgG (Sigma)
was added at a dilution of 1 : 5000 in blocking buffer. After a 1 h
incubation at 37uC, the plates were washed and the colour developed
using OPD solution. Colour development was stopped after 10 min
by adding 1 M H2SO4. The colour was read in an ELISA plate reader
using a 492 mm filter.
RESULTS
Recovery of recombinant viruses from cloned
cDNA
In order to rescue virus from cDNA clones, Vero cells were
transfected with the full-length genome plasmid pRPV-
PPRN or pRPV2C along with helper N, P and L plasmids.
Cells transfected with pRPV-PPRN showed signs of CPE
3–4 days following transfection, at the same time as the
control RPV plasmid pRPV2C. Two independent cDNA
clones of RPV–PPRN virus were rescued; however, only
one was used for further characterization. In order to
confirm the identity of the recombinant virus, the N gene
was amplified using the PCR primer set PPRNF/PPRNR,
which produced an amplified product of the expected size
(data not shown). No PCR products were generated in
parallel reactions in which the reverse transcriptase was
omitted, indicating that the amplified products were not
generated from the transfected plasmid DNA. The PCR
products were sequenced to ensure that they were from the
expected virus. In order to study the plaque morphology of
the chimeric virus, Vero cells infected with the parental or
chimeric virus were overlaid with carboxy methyl cellulose
and the plaques were stained with Giemsa. Phenotypically,
RPV–PPRN virus was found to be more or less similar to
the parent viruses, i.e. small syncytia were observed (data
not shown).
Growth of chimeric virus in tissue culture
Standard multi-step growth curves for the recombinant
and the parental viruses were carried out in Vero cells in-
oculated with an equal m.o.i. of each virus (Fig. 1).
Although slower growth of the chimeric virus was observed
at 24 h post-infection, it grew to a titre similar to the
parental viruses by 36 h post-infection and remained the
same on further incubation. Both the kinetics and
Fig. 1. Growth of different viruses in tissue culture. Growth rates
of viruses were determined under multi-step growth conditions
(m.o.i. of ~0.01) for normal RPV, PPRV and the chimeric RPV–
PPRN virus in Vero cells. Results are shown as the mean of
duplicate readings.
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comparable to those of the parental viruses, indicating
that the recombinant virus was fully competent for multi-
cycle growth in vitro. This experiment was repeated with
similar results.
In vivo characterization of RPV–PPRN virus
A preliminary vaccination trial was carried out to study the
effectiveness of the chimeric virus in generating protective
immunity and stimulating an antibody response in the
natural host species (cattle) by comparing it with the
parental rinderpest vaccine. At 6 weeks post-vaccination,
all cattle were challenged with the highly virulent RPV
Saudi 1/81 strain. A control group was not included in the
experiment, as the challenge virus was from a batch of well-
characterized, freeze-dried virus that has been used in
previous animal experiments and is known to be highly
virulent (Kamata et al., 2001; Walsh et al., 2000b). No
specific signs of clinical disease associated with RPV
infection were observed in any of the five RPV–PPRN-
or RPV-vaccinated cattle following vaccination. The rectal
temperature and leukocyte counts of the animals employed
in this study were monitored for 2 weeks post-vaccination
and challenge as indicators of subclinical disease. The rectal
temperature of all of the vaccinated animals remained
within the normal range following vaccination (data not
shown). In the majority of vaccinated animals, there was
an initial leukopenia on day 2, after which levels returned
to normal (Fig. 2a). This mild leukopenia is commonly
observed in cattle vaccinated with the standard RBOK
vaccine and indicates replication of the vaccine virus.
Following challenge, none of the vaccinated animals
showed any constant rise in body temperature (data not
shown) or exhibited any rinderpest-specific clinical signs. A
mild transient leukopenia was observed following challenge
in two animals, one from each group (Fig. 2b), suggesting
minimal replication of the challenge virus. A much more
dramatic and severe leucopenia occurs in animals infected
with virulent RPV (Anderson et al., 1996; Walsh et al.,
2000b)
Detection of virus and viral RNA in clinical
samples
Attempts were made to isolate virus from the PBLs of
vaccinated animals. Virus could be isolated from some
animals vaccinated with chimeric virus on days 2 and 5
(Table 1). This is in agreement with our observation of the
presence of viral RNA in lymphocytes on this day as
evidenced by RT-PCR (Table 2). No viral RNA was detected
in occular swabs during the entire period of the study, a
characteristic of the parental rinderpest vaccine, which is
not spread by contact, indicating it to be a safe vaccine.
Viral RNA in lymphocytes was detected mainly on days 2
and 5 following vaccination, after which it began to dis-
appear and could only be detected by nested PCR (Table 2).
Following challenge, there was evidence of slow replication
of challenge virus in some vaccinated animals, which was
not sufficient to be detected by virus isolation or a simple
diagnostic PCR, but could be detected in some animals by
the more sensitive nested PCR on days 2 and 5 (Table 2).
Detection of H-specific antibodies
cELISA was carried out on serum collected from the vac-
cinated and challenged animals to detect the antibody
response using RPV and PPRV H-specific mAbs as
described in Methods. None of the animals employed in
this study showed an antibody response to RPV H protein
on the day of vaccination. All animals vaccinated with RPV
or RPV–PPRN showed more than 50% inhibition (the
Fig. 2. Leukocyte counts in the blood of animals following
vaccination (a) and challenge (b). Animals were vaccinated with
RPV2C (UQ9 and UQ10) or RPV–PPRN virus (UQ11, UQ12 and
UQ13) and the leukocyte count per mm
3 of blood was recorded
on days 0, 2, 5, 7, 9, 12 and 14 following challenge.
Table 1. Virus isolation
PBLs isolated from each animal following vaccination and challenge
were co-cultivated with Vero cells. P, Number of animals positive for
virus isolation; T, total number of animals tested. Numbers in
parentheses are values post-challenge.
Day RPV–PPRN (P/T) RPV (P/T)
0 0/3 (0/3) 0/2 (0/2)
2 1/3 (0/3) 1/2 (0/2)
5 1/3 (0/3) 1/2 (0/2)
7 0/3 (0/3) 0/2 (0/2)
9 0/3 (0/3) 0/2 (0/2)
12 0/3 (0/3) 0/2 (0/2)
14 0/3 (0/3) 0/2 (0/2)
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H-specific mAb binding on the day of challenge (Fig. 3a).
Moreover, no appreciable anamnestic response was ob-
served following challenge with the virulent Saudi 1/81
strain, suggesting that only low-level replication of the
challenge virus took place. None of the animals used in the
experiments showed a PPRV H-specific inhibition greater
than 22%, considered non-specific in the test, and it was
always lower than the RPV H-specific inhibition (data not
shown).
Detection of N-specific antibodies using the
currently available cELISA
cELISA was carried out on serum collected from the
experimental animals to measure the RPV and PPRV N-
specific antibody response using the existing N protein-
based cELISA as described in Methods. All animals
vaccinated with either RPV or RPV–PPRN exhibited
more than 50% inhibition of RPV N-specific mAb binding
on the day of challenge. Although the values were higher
for RPV-vaccinated animals, they were not statistically
significant (Fig. 3b). Similarly, all of the animals employed
in this study exhibited more than 50% inhibition of PPRV
N-specific mAb binding on the day of challenge. Although
RPV–PPRN-vaccinated animals exhibited higher values,
again they were not statistically significant (Fig. 3c). These
results clearly showed the cross-reaction of PPRV N-
specific mAb with RPV N protein and vice versa.
Cloning and expression of the C-terminal variable
region of RPV N protein
In order to develop a more-specific ELISA, the coding
region of the C-terminal variable region of RPV N protein
(RPVNv) was amplified by PCR and inserted into the
bacterial expression vector pQE30. An N-terminal His-
tagged protein was expressed efficiently from this vector in
E. coli (Fig. 4a) and found to be soluble in nature. The
RPVNv protein was purified on a Ni-NTA spin column to
near homogeneity as judged by Coomassie blue staining
(data not shown).
Table 2. Detection of RNA extracted from eye swabs (E) or
PBLs by RT-PCR
The PCR product obtained using the diagnostic primer set (F3/F4)
was used as template for the nested PCR using primer set F3a/F4a. P,
Number of animals positive for the presence of viral RNA; T, total
number of animals tested; NT, not tested. Data in parentheses indicate
values post-challenge.
Day Sample RPV–PPRN RPV
F3/F4
(P/T)
F3a/F4a
(P/T)
F3/F4
(P/T)
F3a/F4a
(P/T)
0 E 0/3 (0/3) 0/3 (0/3) 0/2 (0/2) 0/2 (0/2)
PBLs 0/3 (0/3) 0/3 (0/3) 0/2 (0/2) 0/2 (0/2)
2 E 0/3 (0/3) 0/3 (0/3) 0/2 (0/2) 0/2 (0/2)
PBLs 3/3 (0/3) NT (1/3) 2/2 (0/2) NT (1/2)
5 E 0/3 (0/3) 0/3 (0/3) 0/2 (0/2) 0/2 (0/2)
PBLs 1/3 (0/3) 1/2 (1/3) 1/2 (0/2) 1/1 (1/2)
7 E 0/3 (0/3) 0/3 (0/3) 0/2 (0/2) 0/2 (0/2)
PBLs 0/3 (0/3) 0/3 (0/3) 0/2 (0/2) 0/2 (0/2)
9 E 0/3 (0/3) 0/3 (0/3) 0/2 (0/2) 0/2 (0/2)
PBLs 0/3 (0/3) 0/3 (0/3) 0/3 (0/2) 0/2 (0/2)
12 E 0/3 (0/3) 0/3 (0/3) 0/2 (0/2) 0/2 (0/2)
PBLs 0/3 (0/3) 0/3 (0/3) 0/2 (0/2) 0/2 (0/2)
14 E 0/3 (0/3) 0/3 (0/3) 0/2 (0/2) 0/2 (0/2)
PBLs 0/3 (0/3) 0/3 (0/3) 0/2 (0/2) 0/2 (0/2)
Fig. 3. Antibody response in animals subjected to vaccination and
challenge. Serum collected at regular intervals from animals
vaccinated with RPV2C (UQ9 and UQ10) or RPV–PPRN virus
(UQ11, UQ12 and UQ13) was analysed by cELISA for specific
inhibition of RPV H (a), RPV N (b) and PPRV N (c) using mAbs
(see Methods for details). The cut-off value between negative and
positive results was taken as 50% inhibition and the mean of
duplicate readings is plotted. Arrows indicate the day of challenge.
dpv, Days post-vaccination; dpc, days post-challenge.
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recombinant RPVNv antigen in an indirect ELISA
An indirect ELISA was carried out as described in Methods
on serum collected from the vaccinated and challenged
animals to detect the antibody response to N protein using
the E. coli-expressed RPVNv as the antigen. Animals vac-
cinated with RPV–PPRN virus were found to be negative
for RPV N-specific antibodies following vaccination.
Following challenge with virulent RPV (containing RPV
N), the animals remained negative in the RPV N-specific
indirect ELISA (Fig. 4b), suggesting that the low level of
replication of the challenge virus was not sufficient to elicit
a specific antibody response. Animals vaccinated with RPV
showed significantly higher levels of RPV N-specific
antibodies in comparison with animals vaccinated with
RPV–PPRN vaccine on the day of challenge and 1 and 2
weeks following challenge (Fig. 4b). No cross-reaction of
the rinderpest antigen (RPVNv) with the PPRV N-elicited
antibodies was observed, reflecting the fact that this test
can be used as a diagnostic tool for serological identifica-
tion of animals vaccinated with the RPV–PPRN marker
vaccine and also for differentiation of RPV- and PPRV-
infected animals.
Neutralizing antibody titres
Serum neutralization assays were carried out to determine
the virus neutralizing antibody titres to RPV, if any, in the
serum of vaccinated animals before and after challenge
with virulent RPV. As shown in Table 3, on day 0, all of the
animals were negative for the presence of RPV-specific
neutralizing antibody and all of the vaccinated animals
had significant neutralizing antibody titres on the day of
challenge (ranging from log 3.81 to 4.18). The neutralizing
antibody titre of the RPV–PPRN group was found to be as
high as that of the RPV group, indicating the chimeric
virus to be as immunogenic as the parental RPV.
DISCUSSION
The paramyxovirus N protein plays an essential role in
virus replication by associating with the P and L proteins
and is also involved in encapsidation of the viral genome to
form the ribonucleocapsid. N–N, N–P, N–P+L and N–M
interactions have been reported in paramyxoviruses
(Buchholz et al., 1994; Coronel et al., 2001; Curran, 1996;
Curran et al., 1998; Ryan & Portner, 1990), indicating the
diverse functional nature of the N protein. Alignment of
morbillivirus N protein amino acid sequences has defined
four regions (I–IV) with varying degrees of sequence
homology (Diallo et al., 1994; Griffin & Bellini, 1996). The
amino acids in region I (aa 1–122) are well conserved,
whereas the residues in region II (aa 123–144) show low
sequence homology. Region III (aa 145–420) represents the
central highly conserved area, whereas the amino acids in
region IV (aa 421–525) at the C terminus are the least
conserved. Sequence analysis of PPRV and RPV N proteins
revealed amino acid sequence identities of 81.8, 40.9, 90.5
Fig. 4. (a) Expression of RPVNv protein in E. coli. E. coli strain
M15 was transformed with the expression plasmid encoding
RPVNv protein and grown as described in Methods. Cell lysates
were prepared and analysed by 12% SDS-PAGE. The gel was
stained with Coomassie blue and photographed. M, Marker; lane
1, cell lysate from M15 control cells; lanes 2–5, cell lysate from
clones 1–4 expressing RPVNv protein. The position of the N
protein is indicated by an arrow. (b) Antibody response in animals
subjected to vaccination and challenge. Serum collected at regular
intervals from animals vaccinated with RPV2C (UQ9 and UQ10) or
RPV–PPRN virus (UQ11, UQ12 and UQ13) was analysed by
indirect ELISA using bacterially expressed RPVNv protein as
antigen (see Methods for details). Results are expressed as
absorbance values and the mean of duplicate readings is plotted.
Arrows indicate the day of challenge.
Table 3. Serum neutralizing antibody responses to RPV in
cattle vaccinated with RPV–PPRN or RPV
Results are given as the log10 titre that gave 50% neutralization.
–, Negative result.
Week (post-
vaccination)
RPV RPV–PPRN
UQ9 UQ10 UQ11 UQ12 UQ13
0 22 2 2 2
1 1.45 1.45 1.45 2.2 2.05
2 3.05 2.98 3.13 2.75 2.68
6 3.81 4.18 4.18 4.11 4.11
7 4.26 4.48 4.33 4.41 4.41
8 3.96 4.18 4.11 4.37 4.41
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In rescue experiments involving morbillivirus or pneumo-
virus mini-genomes, only homologous sets of helper plas-
mids derived from one virus are able to generate efficient
reporter gene expression from heterologous mini-genome
constructs (Brown et al., 2005; Stokes et al., 2003). Mixed
sets of helper plasmids function only in certain combina-
tions, whilst others are inactive or give only a very low level
of activity. In fact, substitution of a homologous N helper
plasmid with a heterologous N helper plasmid leads to
abolition of the reporter gene activity in MV (Brown et al.,
2005), RPV (Brown et al., 2005) and the pneumovirus
respiratory syncytial virus (Stokes et al., 2003). The incom-
patibility of heterologous combinations of helper plasmids
to rescue mini-genome reporter genes or full-length gen-
omic constructs in paramyxoviruses and pneumoviruses
(Brown et al., 2005; Govindarajan et al., 2006) is not
unexpected considering, as indicated above, the diverse
functions of the N protein. Therefore, it was remarkable
that substitution of the N gene in the RPV chimera was
successful and fully functional, indicating that the N
protein of RPV is replaceable with that of the related
PPRV. In contrast, the H protein gene of RPV cannot be
replaced with that of PPRV; virus can be rescued only when
both the H and F genes are substituted together (Das et al.,
2000). In addition, it requires the presence of the PPRV M
protein gene for efficient growth in cell culture (Mahapatra
et al., 2006). The PPRV N gene has been reported to be
68.8% identical at the nucleotide level and 72.9% similar
at the amino acid level to the RPV N gene, the highest value
when compared with other morbilliviruses (Diallo et al.,
1994), and therefore the success of recovering virus from a
RPV cDNA clone where the N protein gene has been
replaced with that from PPRV may be partly attributable to
this high degree of sequence conservation. The chimeric
virus reported here had an initial slow growth, which was
compensated following further incubation, and it grew to a
final titre as high as the parental RPV, as has been observed
in a recombinant NDV where an immunodominant epitope
in the N protein was deleted (Mebatsion et al., 2002). The
only other report showing the exchange of N proteins
between two related paramyxoviruses is by Bailly et al.
(2000). They recovered a viable recombinant human para-
influenzavirus 3 (HPIV3) where the N gene ORF was
replaced with that from bovine parainfluenzavirus 3
(BPIV3) and the recombinant virus also grew to a titre as
high as that of the parental HPIV3 and BPIV3.
A global rinderpest eradication programme is currently
under way with a target date of 2010 to achieve this goal.
As a result of this effort, rinderpest has been eliminated
from Asia and is now confined to southern Somalia in
eastern Africa. All countries, including Somalia, have now
ceased vaccination and have started intensive disease
surveillance and serosurveillance to detect rinderpest anti-
bodies in non-vaccinated animals. Part of the final strategy
for eradication of rinderpest is an emergency vaccination
plan to prevent spread of the virus in the event of isolated
outbreaks of disease in the endemic region. For this
eventuality, it is desirable to have a ‘marker vaccine’, which
would enable identification of the vaccinated animals
serologically and so not interfere with the ongoing sero-
surveillance work in other regions of the African continent.
Using reverse genetics techniques, positively marked
vaccines have been produced for rinderpest (Walsh et al.,
2000a, b). These vaccines are highly effective in protecting
animals from virulent rinderpest challenge. However, if
these vaccines are used, it will not be possible to identify
vaccinated animals that subsequently become infected, and
this could then mask the presence of the wild-type virus.
We have now produced a negative marker vaccine by
replacing the N protein gene of RPV with the equivalent
gene from PPRV. This vaccine does not produce a strong N
protein-specific antibody response as found in natural
infection or in traditional vaccination.
A preliminary vaccination trial was conducted to evaluate
the chimeric RPV–PPRN virus as a marker vaccine and
also to compare its efficacy with the tissue-culture-
attenuated Plowright rinderpest vaccine. The absence of
clinical response, including fever and leukopenia, showed
that the vaccine is safe to use, at least in cattle. Moreover,
the absence of viral RNA in ocular secretions throughout
the period of study, as evidenced by RT-PCR, further
confirmed its safety. Neutralizing antibodies were detected
in all vaccinated animals, and animals vaccinated with the
chimeric vaccine exhibited comparable neutralizing anti-
body titres to the RPV-vaccinated animals, indicating the
chimeric virus to be as immunogenic as the parental RPV.
All of the animals were protected against virulent virus
challenge, indicating that it is an efficacious vaccine. The
cELISA based on responses to the H protein showed that all
of the vaccinated animals were positive for RPV-specific
anti-H antibodies, whereas they remained negative for
PPRV H-specific inhibition at 6 weeks following vaccina-
tion. However, the existing N protein-based cELISAs to
detect antibodies against the RPV and PPRV N proteins
were found to cross-react with each other and therefore
were not suitable for use as serological tests with this new
chimeric vaccine. Our results confirmed those reported
previously on cross-reactivity between the two tests (Diallo,
2000). In order to circumvent this problem, we expressed
the RPVNv protein in E. coli and used it in an indirect
ELISA. The new RPVNv ELISA clearly did not show cross-
reaction with PPRV N antibodies and is therefore suitable
for use as a companion diagnostic test with this vaccine.
The lack of response to RPVNv following challenge indi-
cated that the vaccine provided sterile immunity to rinder-
pest, at least in the short term, as for the conventional
Plowright tissue culture vaccine. As the RPV–PPRN vaccine
lacks the highly antigenic RPV N protein, it can be used as
a marker RPV vaccine to distinguish serologically between
vaccinated and naturally recovered animals. The animals
vaccinated with the chimeric vaccine will be positive in
RPV H cELISA and negative in RPVNv ELISA, whereas the
Chimeric rinderpest virus
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be positive in both tests. However, large-scale trials involv-
ing a much larger number of animals of different age, sex,
breed and physiological status need to be carried out to
establish further the safety of this chimeric virus before it
can be used in the field. There is a plan to test this chimeric
vaccine in a larger number of the target species of different
African cattle breeds.
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